Sarepta Therapeutics (SRPT) revenue breakdown
By product, PMO Products is the largest at 52% of fiscal 2025 revenue; ELEVIDYS grew fastest, 112% a year over 2 years.
Revenue by product
Fiscal years, as Sarepta Therapeutics reports them in its 10-K filings; fiscal 2025 total $1.9B.
| Products | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|
| PMO Products | $945M | $967M | $966M | 52% |
| ELEVIDYS | $200M | $821M | $899M | 48% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for SRPT.
Open SRPT in InvestinglyQuestions
Where does Sarepta Therapeutics make its money?
In fiscal 2025, by product: PMO Products $966M, ELEVIDYS $899M.
From Sarepta Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.